Scholarlink

Purpose <p>To investigate the predictive performance of PD-L1 expression and tumor-infiltrating lymphocytes (TILs) in pre-treatment biopsies for the response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC).</p> Methods <p>This retrospective study included 82 NSCLC patients who received neoadjuvant chemoimmunotherapy. PD-L1 expression (tumor cell [TC%], immune cell [IC%], and combined positive score [CPS]), TILs density, and the lymphocyte-to-tumor ratio (LTR) were quantitatively assessed using digital image analysis (IA). Diagnostic performance was evaluated for major pathological response (MPR), pathological complete response (pCR), and event-free survival (EFS).</p> Results <p>Of the 82 patients, 48 (58.5%) achieved MPR and 25 (30.5%) achieved pCR. TC%-IA and TILs density were significantly associated with pathological response. For predicting MPR, TC%-IA (AUC = 0.67) showed better performance than IC%-IA (AUC = 0.61) and CPS-IA (AUC = 0.66). Similarly, for pCR, TC%-IA (AUC = 0.59) outperformed IC%-IA (AUC = 0.55) and CPS-IA (AUC = 0.47). TILs density yielded AUCs of 0.70 for MPR and 0.69 for pCR, while LTR-IA achieved AUCs of 0.71 and 0.61, respectively. The combination of TC%-IA ≥ 1% and LTR-IA ≥ 1 further improved predictive performance, with AUCs of 0.76 for MPR and 0.67 for pCR. Prognostic analysis showed that TC%-IA ≥ 1%, CPS-IA ≥ 10, and LTR-IA ≥ 1 were significantly associated with prolonged EFS.</p> Conclusions <p>Image-based PD-L1 scoring on TC% combined with LTR ≥ 1 serves as a predictive biomarker for both pathological response and EFS in NSCLC patients receiving neoadjuvant chemoimmunotherapy. LTR can serve as a surrogate for TILs scoring and predicts long-term EFS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Image-based PD-L1 scoring and tumor-infiltrating lymphocytes as predictors for the response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer

  • 期刊论文

  • 发表日期：

    2026年4月9日

查看全文
  • Jianghua Wu,
  • Wei Sun,
  • Xinying Liu,
  • Xin Yang,
  • Luning Mao,
  • Chenglong Wang,
  • Xinting Diao,
  • Dongmei Lin

摘要

Purpose

To investigate the predictive performance of PD-L1 expression and tumor-infiltrating lymphocytes (TILs) in pre-treatment biopsies for the response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC).

Methods

This retrospective study included 82 NSCLC patients who received neoadjuvant chemoimmunotherapy. PD-L1 expression (tumor cell [TC%], immune cell [IC%], and combined positive score [CPS]), TILs density, and the lymphocyte-to-tumor ratio (LTR) were quantitatively assessed using digital image analysis (IA). Diagnostic performance was evaluated for major pathological response (MPR), pathological complete response (pCR), and event-free survival (EFS).

Results

Of the 82 patients, 48 (58.5%) achieved MPR and 25 (30.5%) achieved pCR. TC%-IA and TILs density were significantly associated with pathological response. For predicting MPR, TC%-IA (AUC = 0.67) showed better performance than IC%-IA (AUC = 0.61) and CPS-IA (AUC = 0.66). Similarly, for pCR, TC%-IA (AUC = 0.59) outperformed IC%-IA (AUC = 0.55) and CPS-IA (AUC = 0.47). TILs density yielded AUCs of 0.70 for MPR and 0.69 for pCR, while LTR-IA achieved AUCs of 0.71 and 0.61, respectively. The combination of TC%-IA ≥ 1% and LTR-IA ≥ 1 further improved predictive performance, with AUCs of 0.76 for MPR and 0.67 for pCR. Prognostic analysis showed that TC%-IA ≥ 1%, CPS-IA ≥ 10, and LTR-IA ≥ 1 were significantly associated with prolonged EFS.

Conclusions

Image-based PD-L1 scoring on TC% combined with LTR ≥ 1 serves as a predictive biomarker for both pathological response and EFS in NSCLC patients receiving neoadjuvant chemoimmunotherapy. LTR can serve as a surrogate for TILs scoring and predicts long-term EFS.